Roseburia intestinalis (next-generation butyrate-producing probiotic)
Roseburia intestinalis is a beneficial gut bacterium that — alongside Faecalibacterium prausnitzii (Camden's separate entry) — produces most of the butyrate in your large intestine. Butyrate is the short-chain fatty acid your colon cells use as their preferred energy source, and that supports the gut-barrier and immune signalling. Roseburia is typically 1-5% of the bacteria in a healthy adult's stool sample, and its abundance is reduced in inflammatory bowel disease, irritable bowel syndrome, type 2 diabetes, obesity, atherosclerosis, and after antibiotic courses. Like F. prausnitzii, Roseburia is extremely sensitive to oxygen — it cannot survive air exposure for more than a couple of minutes. This makes direct probiotic capsule supplementation technically demanding, and commercial UK availability is essentially research-stage. The Tamanai- Shacoori 2017 Future Microbiol review (PMID 28139139) and Nie 2021 Front Cell Infect Microbiol review (PMID 34881193) summarise the genus as a "marker of health" — reduced abundance correlates with multiple chronic diseases, the mechanism (butyrate + flagellin + barrier homeostasis) is robust, but direct intervention RCTs are sparse. Camden Medicals does NOT currently retail Roseburia intestinalis. The entry serves as the next-generation- probiotic cluster reference alongside Camden's faecalibacterium-prausnitzii + akkermansia-muciniphila entries. For UK consumers researching this space: this is research-stage probiotic science. The practical route to increase your endogenous Roseburia is prebiotic dietary fibre — resistant starch (cooked-and-cooled potatoes / rice, green bananas), inulin / oligofructose (chicory, onions, garlic, leeks), β-glucan (oats, barley), psyllium, pectin (apples, citrus). UK NHS Eatwell Guide 30 g/day fibre target supports this.
Camden Medicals editorial · Last reviewed 12 May 2026 · Next review November 2026
- Cross-checked against
- NHS
- NICE
- BNF
- EFSA
- FSA
Camden's editorial team independently graded each health claim below on the strength of the published evidence — see the grade beside every condition.
- Class
- Probiotic
- Typical daily dose
- Direct supplementation research-stage; commercial dose patterns not established.
- Top use evidence
- Limited
On this page
What it is
Roseburia intestinalis is a Gram-positive, slightly curved rod-shaped, peritrichously flagellated, strictly anaerobic bacterium of the Firmicutes phylum (Clostridia class, Clostridiales order, Lachnospiraceae family). It was first described in 2002 (Duncan et al., from human faecal samples).
Distinguishing features:
- Butyrate producer via butyrate-kinase pathway — distinct from F. prausnitzii's butyryl-CoA:acetate CoA-transferase pathway. Different metabolic route; same end-product.
- Motile — unusual among major colonic bacteria. Peritrichous flagella + active motility through colonic mucus layer.
- 1-5% relative abundance in healthy adult colonic microbiota.
- Reduced abundance documented in IBD (Machiels 2014 Gut), IBS, T2D + obesity, atherosclerosis (Karlsson 2012 Nature), post-antibiotic dysbiosis.
Commercial supplement availability: research-stage. Same oxygen-sensitivity challenges as F. prausnitzii limit live probiotic delivery. Pasteurised / heat-killed preparations + microbiologically stable derivatives under development. Pendulum-type metabolic-microbiome blends include Anaerobutyricum (related Lachnospiraceae butyrate producer) but rarely Roseburia specifically.
Distinct from F. prausnitzii (Camden faecalibacterium-prausnitzii) — both are major butyrate producers but use different metabolic pathways + occupy slightly different colonic niches.
At a glance
- Major butyrate-producing gut bacterium alongside F. prausnitzii. 1-5% of healthy human faecal microbiota.
- Reduced abundance in IBD (Machiels 2014 Gut), IBS, T2D + obesity, atherosclerosis (Karlsson 2012 Nature), post-antibiotic dysbiosis. Tamanai-Shacoori 2017 PMID 28139139 + Nie 2021 PMID 34881193 review the "marker of health" framework.
- Commercial supplement availability: research-stage. Same strict-anaerobe oxygen-sensitivity challenges as F. prausnitzii limit live probiotic delivery.
- Different metabolic pathway than F. prausnitzii (butyrate kinase vs butyryl-CoA:acetate CoA-transferase) — different routes, same end-product butyrate. Roseburia is motile via peritrichous flagella (unusual among major colonic bacteria).
- NO UK-authorised health claims. UK NICE NG129/NG130/NG28/CKS IBS do NOT include Roseburia. Genuinely emerging research-stage probiotic.
- Best practical support: prebiotic dietary fibre (resistant starch, inulin, β-glucan, psyllium, pectin) supports endogenous Roseburia + F. prausnitzii growth alongside other butyrate producers.
What people use it for
Adults with IBD, IBS, metabolic syndrome
Reduced Roseburia abundance documented in these contexts. Direct supplementation research-stage. UK NICE NG129 (Crohn) / NG130 (UC) / NG28 (T2D) / CKS IBS pathways apply. [1,2,3]
Popular, not provenInsufficientAdults supporting general microbiome diversity
Indirect support via prebiotic dietary fibre (resistant starch, inulin, β-glucan, pectin, psyllium) supports endogenous Roseburia + butyrate-producer ecosystem. [5]
Some evidenceLimitedPregnant or breastfeeding women
Limited safety data for direct supplementation. Prebiotic fibre intake from food is fine. [9]
Popular, not provenInsufficientSeverely immunocompromised adults
Caution with all live probiotic strains. Talk to clinical team.
Some evidenceLimited
How it works
Butyrate production via butyrate-kinase pathway. Roseburia ferments dietary oligosaccharides + resistant starch + cellulose + xylan → acetate + lactate, then converts these via butyryl-CoA → butyryl-phosphate → butyrate via butyrate kinase. F. prausnitzii uses a different terminal enzyme (butyryl-CoA:acetate CoA-transferase). The two species occupy slightly different colonic niches + metabolic substrates.
Same downstream butyrate effects as F. prausnitzii — colonocyte energy substrate; tight-junction barrier-protein support; histone deacetylase inhibition + Treg-cell induction; anti-inflammatory cytokine modulation.
Mucus-layer interaction. Roseburia motility (peritrichous flagella) allows movement through the colonic mucus layer — distinct from non-motile F. prausnitzii. The mucus-penetration mechanism has been studied for IBD-relevant barrier-function support.
Cardiovascular adjacency. Karlsson 2012 (Nature) reported reduced Roseburia abundance in symptomatic atherosclerosis vs healthy controls. Mechanism may involve butyrate-mediated lipid metabolism + LPS-translocation reduction. Translation to therapeutic intervention is research-stage.
Limitations. Same as F. prausnitzii: strict-anaerobe oxygen sensitivity makes commercial probiotic delivery technically demanding. Direct supplementation evidence is research-stage; indirect support via prebiotic fibre intake is the well-evidenced approach.
Common myths
Myth""Roseburia and F. prausnitzii are interchangeable.""
RealityBoth major butyrate producers via different metabolic pathways. Different ecological niches; reduced abundance pattern in disease can differ. Both worth supporting through prebiotic fibre intake.
Myth""Take Roseburia for IBD.""
RealityDirect supplementation research-stage. UK NICE NG129 / NG130 use biologic / immunosuppressant therapy. Prebiotic fibre intake supporting endogenous Roseburia is an adjunct lifestyle measure. [1,2]
What people say online
Roseburia discourse on TikTok and Reddit is smaller than the Akkermansia / F. prausnitzii clusters — most people have not heard of it. Discourse clusters around three narratives: "the missing butyrate-producer probiotic" (mechanism-supported, commercially unavailable); prebiotic fibre as the practical route (mostly accurate); and "leaky gut / IBD healing" (overstated relative to evidence). This section surfaces the discourse without naming individuals.
Trending claims
- TikTok #IBD + r/microbiomelow visibility
Claim: Roseburia is the missing probiotic for IBD
Reality check: Mechanism-supported framing. Reduced Roseburia abundance is documented across IBD studies (Machiels 2014 Gut) and the butyrate-production mechanism is relevant to colonic-barrier function. But direct supplementation is research-stage; commercial Roseburia products are essentially unavailable in UK retail. UK NICE NG129/NG130 pathways do not include Roseburia. [8]
- TikTok #fibremicrobiome + r/microbiomemedium visibility
Claim: Eat fibre to boost Roseburia
Reality check: Accurate. Prebiotic dietary fibre (resistant starch, inulin, β-glucan, psyllium, pectin) supports endogenous Roseburia growth alongside other butyrate-producing bacteria (F. prausnitzii, Eubacterium rectale, Coprococcus). UK NHS Eatwell Guide 30 g/day fibre target underpins the dietary route. This is the best-evidenced practical approach.
- TikTok #heartdisease + cardiovascular Redditlow visibility
Claim: Roseburia reverses atherosclerosis
Reality check: Karlsson 2012 Nature reported reduced Roseburia abundance in symptomatic atherosclerosis vs healthy controls — an observational association, not evidence of reversal via supplementation. UK NICE NG181 (Cardiovascular) pathway uses statins, blood-pressure control, and lifestyle. Roseburia is not in the pathway and direct intervention RCTs do not exist.
- TikTok + supplement-industry Redditlow visibility
Claim: Pendulum products contain Roseburia
Reality check: Mostly inaccurate. Pendulum products contain Anaerobutyricum (a related Lachnospiraceae butyrate producer) but generally do NOT contain Roseburia intestinalis specifically. Read the label carefully — related-genus butyrate producers are not the same as Roseburia.
Where the conversation lives
- TikTok hashtags: #roseburia, #butyrate, #microbiome, #guthealth, #fibre, #IBD
- Reddit subs: r/microbiome, r/IBS, r/Probiotics, r/CrohnsDisease, r/UlcerativeColitis
- Forums: ZOE community, Crohn's and Colitis UK, Examine.com
Questions people are searching
- How do I increase Roseburia naturally?
- Roseburia vs F. prausnitzii?
- Is Roseburia in any commercial probiotic?
- Will fibre actually boost my butyrate producers?
Who drives the discourse: The discourse is driven by three creator classes: microbiome / functional-medicine creators (Roseburia as part of the broader gut-health framing — mostly accurate when surfacing the prebiotic-fibre route); IBD-patient creators (the missing-probiotic framing — mechanism- supported but supplementation-unavailable); and research- translation creators (citing Machiels 2014, Karlsson 2012, Tamanai-Shacoori 2017, Nie 2021 — accurate science communication). Verifera editorial does not name individuals.
Social-media trends change quickly. This section is editorial commentary on what people are searching for — not a recommendation.
Common online questions
Synthesised from the questions UK shoppers most often ask online about Roseburia intestinalis (next-generation butyrate-producing probiotic). Each answer is editorial and links to its evidence in the Sources list below.
How do I support Roseburia in my gut?
Prebiotic fibre intake same as F. prausnitzii: resistant starch (cooked-cooled potatoes, beans, lentils, green bananas), inulin (chicory, asparagus, garlic, onions), β-glucan (oats, barley), pectin (apples, citrus), psyllium husk. Fermented foods (kefir, kombucha, sauerkraut, kimchi) for broader microbiome support. [5]
Is Roseburia in any commercial probiotic?
Rarely. Strict-anaerobe oxygen sensitivity makes commercial delivery technically demanding. Research-stage. Pendulum-style products include the related Lachnospiraceae Anaerobutyricum but rarely Roseburia itself.
UK regulatory landscape
UK regulatory tier: Food supplement
Roseburia sits at the food-supplement-tier edge under the UK Food Supplements (England) Regulations 2003 — direct supplementation would require Novel Food assessment given the absence of historical food-use record. NO UK-authorised Article 13.1 health claim; EFSA Article 13 generic-probiotic evaluations on hold. Commercial UK availability is essentially nil at this time.
What crosses the tier
| Condition | Crosses to |
|---|---|
| Marketing for diagnosed IBD, IBS, T2D, or atherosclerosis as treatment | |
| Direct live Roseburia supplementation without Novel Food authorisation |
Permitted claims
NO UK Article 13.1 authorised health claim exists for Roseburia. Generic factual description (e.g., "Roseburia intestinalis is a butyrate-producing bacterium found in healthy human colon") is permitted.
Cross-jurisdiction note
Roseburia is a research-stage probiotic across all major jurisdictions. No major regulatory body has authorised disease-treatment claims. EU/UK Novel Food framework applies for direct supplementation.
UK regulatory rules evolve. This summary is editorial — businesses should consult regulatory counsel; consumers should consult their pharmacist or GP.
🔬 Camden’s evidence review
The research Camden reviewed, graded on its strength. This is our own appraisal — it sits beneath the official guidance above, never above it.
IBD — abundance association
ModerateEvidencemoderateMachiels 2014 Gut — reduced Roseburia abundance in ulcerative colitis. Replicated in subsequent studies. Direct intervention evidence limited. [1,2]
T2D / atherosclerosis — abundance association
LimitedEvidencelimitedKarlsson 2012 Nature — reduced Roseburia in symptomatic atherosclerosis. T2D associations replicated. [3]
Direct supplementation as therapeutic intervention
InsufficientEvidenceinsufficientTrial evidence essentially absent. Strict-anaerobe oxygen sensitivity limits commercial probiotic delivery; research-stage.
Clinical literature review
The Roseburia literature is dominated by observational microbiome work: Machiels 2014 Gut documented reduced Roseburia in ulcerative colitis; Karlsson 2012 Nature reported reduced Roseburia in symptomatic atherosclerosis; multiple cohort studies show reduced abundance in T2D and obesity. Tamanai-Shacoori 2017 Future Microbiol PMID 28139139 reviews Roseburia spp. as a "marker of health". Nie 2021 Front Cell Infect Microbiol PMID 34881193 reviews R. intestinalis as a beneficial gut organism with mechanism-supported potential in IBD, T2D, antiphospholipid syndrome, atherosclerosis. Direct human RCTs of Roseburia supplementation are essentially absent because of the delivery challenges. UK NICE pathways do NOT include Roseburia in any indication.
Key trials
Tamanai-Shacoori Z, Smida I, Bousarghin L, Loreal O, Meuric V, Fong SB, Bonnaure-Mallet M, Jolivet-Gougeon A · 2017 · Future Microbiol · PMID 28139139
Finding: Comprehensive review of the Roseburia genus (5 species including R. intestinalis, R. hominis, R. inulinivorans, R. faecis, R. cecicola) as commensal short-chain-fatty- acid (especially butyrate) producers. Reduced Roseburia abundance is associated with several diseases including IBS, obesity, T2D, nervous-system conditions, and allergies. The genus could serve as biomarkers for symptomatic pathologies (gallstone formation) or as probiotic candidates for restoration of beneficial gut flora.
Relevance: The most-cited review framing Roseburia as "marker of health". Observational and mechanism work supports the association; direct supplementation evidence remains scarce. UK NICE pathway inclusion: none.
Nie K, Ma K, Luo W, Shen Z, Yang Z, Xiao M, Tong T, Yang Y, Wang X · 2021 · Front Cell Infect Microbiol · PMID 34881193
Finding: R. intestinalis is an anaerobic, Gram-positive butyrate producer that prevents intestinal inflammation and maintains energy homeostasis. IBD patients show significant changes in R. intestinalis abundance. Regulates barrier homeostasis, immune cells, and cytokine release via butyrate, flagellin, and other metabolites. Recent advances (culture omics, single- cell sequencing, metabolomics) have improved research on R. intestinalis and revealed benefits in human health and disease treatment.
Relevance: The most-recent comprehensive review of R. intestinalis clinical translation. Confirms the mechanism + observational association but flags the absence of direct intervention RCTs. Supports the prebiotic-fibre dietary route over direct supplementation.
Systematic reviews
- pmid:28139139
Tamanai-Shacoori 2017 Future Microbiol — review of Roseburia genus as commensal SCFA producers and biomarker of health; reduced abundance associated with IBS, obesity, T2D, nervous-system conditions, allergies.
- pmid:34881193
Nie 2021 Front Cell Infect Microbiol — R. intestinalis as beneficial butyrate-producing gut organism with mechanism in IBD, T2D, atherosclerosis. Direct intervention evidence remains research-stage.
Evidence quality summary
Reduced Roseburia abundance as biomarker across IBD, T2D, obesity, atherosclerosis — HIGH certainty (multiple cohort studies). Mechanism (butyrate production + flagellin signalling + barrier homeostasis) — HIGH certainty in cell-biology and animal models. Direct Roseburia supplementation as a clinical intervention — INSUFFICIENT certainty (technical delivery challenges + absent RCTs). Prebiotic-fibre-mediated indirect support — MODERATE certainty (well-established mechanism). UK NICE pathway inclusion — NONE.
Known gaps
- Direct human RCTs of Roseburia or pasteurised preparations in IBD, T2D, atherosclerosis.
- Standardised technical-delivery solutions for live Roseburia capsule supplementation.
- UK NHS pathway assessment for Roseburia in any specific clinical indication.
- Comparative data on Roseburia vs F. prausnitzii vs Akkermansia at matched indications.
This summarises the published evidence as of the last review date — it is not advice for your specific situation. Talk to your pharmacist or GP.
Safety
Research-stage probiotic. Indirect dietary support is the best-evidenced approach.
Talk to your pharmacist or GP first if you:
- You have severe immunocompromise — talk to clinical team.
- You have IBD — talk to gastroenterology team.
Common side effects: Generally well-tolerated; trial body small.
Pregnancy and breastfeeding
Direct Roseburia supplementation is research-stage with essentially no UK commercial availability — pregnancy safety data is correspondingly absent. Prebiotic dietary fibre intake (resistant starch, inulin, β-glucan, psyllium, pectin) from food is fine and indirectly supports endogenous Roseburia.
As pregnancy. Prebiotic fibre intake from food fine.
Talk to your GP, midwife, or pharmacist before starting any supplement during pregnancy or breastfeeding.
More clinical detail (for clinicians and informed readers)
Contraindications
- Severe immunocompromise (relative).
- Hypersensitivity to formulation.
Drug interactions
Antibiotics (oral broad-spectrum) · low
Effect: Antibiotics non-selectively reduce gut bacteria including Roseburia. Antibiotic-associated dysbiosis is one of the documented contexts in which Roseburia abundance is reduced.
Mechanism: Direct antibiotic kill of Roseburia and other commensal gut bacteria during antibiotic therapy. The dysbiosis contributes to AAD risk and to slower microbiome recovery post-antibiotic.
Action: If using prebiotic-fibre Roseburia support during antibiotic therapy: continue dietary fibre intake; consider an established probiotic combination (BB-12 + LGG) for AAD prevention. Tell your prescriber.
Source: BNF antibiotics + UK NICE CKS Diarrhoea (adults)
Immunosuppressants in severe immunocompromise — limited data for next-generation probiotic strains; direct supplementation research-stage and not in routine use.
Tell your prescriber if you take any of these combinations. This is not personalised advice.
This is not an exhaustive list. Always tell your prescriber and pharmacist about every supplement you take.
Common side effects
- Mild GI upset on first introduction.
Rare side effects
- Theoretical bacteraemia risk in severe immunocompromise.
How to take it
- Typical supplemental range
- Direct supplementation research-stage; commercial dose patterns not established.
- Timing
- N/A — research-stage.
How to spot quality
Look for
- Strain identification (specific Roseburia intestinalis strain).
- CFU declaration if live form.
- GMP-certified manufacture.
Red flags
- Marketing as a "cure" for IBD / IBS — UK NICE pathways use established interventions.
- No strain identification.
- Cancer-prevention claims of any kind.
Commonly combined with
Other ingredients that share a biological pathway, cofactor relationship, or evidence-backed protocol with this one. Mechanisms below cite primary physiology — not folk pairing. Doses are literature ranges, not recommendations. Talk to your pharmacist or GP before changing your stack, especially if you take prescription medication.
Faecalibacterium prausnitzii (next-generation butyrate-producing probiotic)
Limited evidenceButyrate-producer cluster — both feed colonocytes butyrate substrate via different metabolic pathways.
F. prausnitzii butyryl-CoA:acetate CoA-transferase pathway; Roseburia butyrate kinase pathway. Different routes; same end-product butyrate. Different colonic niches; complementary butyrate-producer ecosystem.
Evidence: Mechanism complementary; both reduced in IBD.
Doses studied: Multi-strain butyrate-producer products (research-stage).
Akkermansia muciniphila (next-generation probiotic)
Limited evidenceNext-generation probiotic cluster — mucin-degrading + butyrate-producing complementary axes.
Akkermansia thickens mucin layer + reduces LPS translocation; Roseburia produces butyrate that fuels colonocytes + supports tight-junction barrier proteins. Both reduced in metabolic syndrome / IBD.
Evidence: Mechanism complementary on barrier-function axis.
Doses studied: Multi-strain product (Pendulum-style).
Beta-Glucan (β-glucan)
Limited evidencePrebiotic fibre — oat / barley β-glucan supports Roseburia butyrate production.
Roseburia ferments dietary β-glucan → butyrate via butyrate-kinase pathway. UK Article 13.1 / Article 14 oat β-glucan cholesterol claim mechanistically supported by butyrate-producer microbiome modulation.
Evidence: Camden beta-glucan covers cluster.
Doses studied: ≥3 g/day oat / barley β-glucan supports endogenous Roseburia.
Kefir (Multi-strain fermented milk)
Limited evidenceFermented-food cluster — broader microbiome support.
Kefir delivers diverse Lactobacillus + yeast biomass; prebiotic fibre supports endogenous Roseburia. Mechanism complementary on microbiome diversity.
Evidence: Mechanism complementary.
Doses studied: Kefir 100-300 mL/day + prebiotic fibre intake.
Bifidobacterium longum
Limited evidenceMicrobiome diversity cluster.
B. longum carbohydrate fermenter + Roseburia butyrate producer. Different mechanisms; complementary on microbiome diversity + SCFA production.
Evidence: Mechanism complementary.
Doses studied: Multi-strain product including Roseburia + B. longum.
Verifera™ editorial perspective
Why it matters. Roseburia is one of the most cited "next-generation probiotic" candidates in microbiome research but with one of the smallest commercial supplement footprints — the strict-anaerobe oxygen sensitivity makes direct delivery technically demanding. Tamanai-Shacoori 2017 (PMID 28139139) framed Roseburia as a "marker of health"; reduced abundance across IBD, T2D, obesity, atherosclerosis is consistent. The Verifera editorial position is to honestly surface this gap (mechanism-strong but trial-thin for direct supplementation) and anchor consumers in the practical dietary route (prebiotic fibre + fermented foods).
Where Camden lands. Camden Medicals does NOT currently retail Roseburia intestinalis. The entry serves as the canonical UK reference for the butyrate-producer next-generation- probiotic cluster alongside Camden's faecalibacterium- prausnitzii + akkermansia-muciniphila entries. For UK consumers researching this space: this is research-stage probiotic science. The practical route is prebiotic dietary fibre (resistant starch, inulin, β-glucan, psyllium, pectin) supporting your existing Roseburia + other butyrate producers. Fermented foods (kefir, kimchi, sauerkraut) add broader microbiome support.
If you want to explore further. Diet first. The UK NHS Eatwell Guide 30 g fibre / day target supports endogenous Roseburia growth via prebiotic substrate. Resistant starch (cooked-and-cooled potatoes / rice, green bananas, oats), inulin / oligofructose (chicory, onions, garlic, leeks, Jerusalem artichokes), β-glucan (oats, barley — see Camden beta-glucan), psyllium husk, pectin (apples, citrus peel) — all support butyrate production. If you have diagnosed IBD or T2D: UK NICE NG129 / NG130 / NG28 pathways come first; Roseburia is research- stage and not in any pathway. Direct supplement availability is essentially nil at this time in UK retail.
How this entry was researched
Authoritative sources consulted:
- NHS Inflammatory bowel disease + Eatwell Guide
- NICE NG129 (Crohn's) + NG130 (UC) + NG28 (T2D) + NG181 (Cardiovascular) + CKS Irritable bowel syndrome
- Crohn's and Colitis UK educational resources
- GB Nutrition and Health Claims (NHC) Register (no authorised Roseburia claim)
- Verifera faecalibacterium-prausnitzii + akkermansia-muciniphila + beta-glucan entries (next-generation-probiotic cluster cross-references)
- PubMed (via E-utilities MCP, 2026-05-12)
PubMed search terms:
Roseburia intestinalis butyrate microbiome inflammatory bowel disease review
Literature search date: 2026-05-12
Sources listed are those consulted by the Verifera™ editorial team. Readers should verify against current authoritative sources.